Marinus Pharmaceuticals Inc
NASDAQ:MRNS
Marinus Pharmaceuticals Inc
NASDAQ:MRNS
Price:
0.55
USD
Market Closed
Market Cap:
$30.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Marinus Pharmaceuticals Inc
NASDAQ:MRNS
|
US |
|
HSC Technology Group Ltd
ASX:HSC
|
AU |
|
A
|
Aaswa Trading and Exports Ltd
BSE:512038
|
IN |
|
Samyang Corp
KRX:145990
|
KR |
|
Samsung SDS Co Ltd
KRX:018260
|
KR |
Balance Sheet
Balance Sheet Decomposition
Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals Inc
Balance Sheet
Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals Inc
Currency: USD
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
50
|
52
|
26
|
34
|
68
|
91
|
139
|
123
|
241
|
121
|
|
| Cash Equivalents |
50
|
52
|
26
|
34
|
68
|
91
|
139
|
123
|
241
|
121
|
|
| Short-Term Investments |
0
|
5
|
4
|
20
|
5
|
1
|
2
|
0
|
0
|
30
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
6
|
4
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
6
|
4
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
| Other Current Assets |
0
|
2
|
0
|
1
|
1
|
3
|
5
|
6
|
5
|
9
|
|
| Total Current Assets |
50
|
58
|
30
|
54
|
74
|
94
|
146
|
132
|
252
|
165
|
|
| PP&E Net |
0
|
0
|
1
|
1
|
1
|
5
|
4
|
4
|
6
|
5
|
|
| PP&E Gross |
0
|
0
|
1
|
0
|
1
|
5
|
4
|
4
|
6
|
5
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
2
|
2
|
|
| Long-Term Investments |
0
|
2
|
0
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
1
|
|
| Total Assets |
50
N/A
|
60
+19%
|
31
-47%
|
61
+93%
|
75
+24%
|
99
+31%
|
151
+52%
|
137
-9%
|
260
+90%
|
171
-34%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
3
|
3
|
1
|
3
|
3
|
2
|
3
|
5
|
4
|
|
| Accrued Liabilities |
2
|
1
|
1
|
2
|
4
|
5
|
9
|
16
|
20
|
23
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
2
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
12
|
|
| Other Current Liabilities |
0
|
1
|
1
|
0
|
0
|
0
|
0
|
21
|
1
|
2
|
|
| Total Current Liabilities |
2
|
7
|
8
|
3
|
7
|
8
|
11
|
41
|
25
|
41
|
|
| Long-Term Debt |
7
|
5
|
2
|
0
|
0
|
0
|
0
|
41
|
71
|
61
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
3
|
3
|
2
|
48
|
52
|
|
| Total Liabilities |
9
N/A
|
13
+40%
|
10
-21%
|
3
-73%
|
7
+156%
|
11
+61%
|
13
+20%
|
83
+527%
|
144
+72%
|
154
+7%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
28
|
5
|
4
|
4
|
0
|
|
| Retained Earnings |
72
|
97
|
126
|
145
|
182
|
236
|
312
|
411
|
431
|
572
|
|
| Additional Paid In Capital |
114
|
144
|
147
|
203
|
250
|
295
|
445
|
460
|
542
|
589
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
41
N/A
|
47
+14%
|
22
-54%
|
58
+170%
|
68
+18%
|
88
+29%
|
137
+56%
|
54
-61%
|
116
+117%
|
17
-86%
|
|
| Total Liabilities & Equity |
50
N/A
|
60
+19%
|
31
-47%
|
61
+93%
|
75
+24%
|
99
+31%
|
151
+52%
|
137
-9%
|
260
+90%
|
171
-34%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
4
|
5
|
5
|
10
|
13
|
22
|
37
|
37
|
50
|
55
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
